SEARCH

SEARCH BY CITATION

References

  • 1
    Brandt JL, Castleman L, Ruskin HD, Greenwald J, Kelly JJ, Jones A. The effect of oral protein and glucose feeding on splanchnic blood flow and oxygen utilization in normal and cirrhotic subjects. J Clin Invest 1955; 34:1017.
  • 2
    Gaiani S, Bolondi L, Li BS, Santi V, Zironi G, Barbara L. Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease. Hepatology 1989; 9:815819.
  • 3
    Lee SS, Hadengue A, Moreau R, Sayegh R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology 1988; 8:647651.
  • 4
    Orrego H, Mena I, Baraona E, Palma R. Modifications in hepatic blood flow and portal pressure produced by different diets. Am J Dig Dis 1965; 10:239248.
  • 5
    Sabba C, Ferraioli G, Buonamico P, Mahl T, Taylor KJ, Lerner E, Albano O, et al. A randomized study of propranolol on postprandial portal hyperemia in cirrhotic patients. Gastroenterology 1992; 102:10091016.
  • 6
    Sabba C, Ferraioli G, Genecin P, Colombato L, Buonamico P, Lerner E, Taylor KJ, et al. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: an operator-blind echo-Doppler study. Hepatology 1991; 13:714718.
  • 7
    Tsunoda T, Ohnishi K, Tanaka H. Portal hemodynamic responses after oral intake of glucose in patients with cirrhosis. Am J Gastroenterol 1988; 83:398403.
  • 8
    O'Brien S, Keogan M, Patchett S, McCormick PA, Afdhal N, Hegarty JE. Postprandial changes in portal haemodynamics in patients with cirrhosis. Gut 1992; 33:364367.
  • 9
    Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, Garcia P, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21:8894.
  • 10
    Bendtsen F, Simonsen L, Henriksen JH. Effect on hemodynamics of a liquid meal alone and in combination with propranolol in cirrhosis. Gastroenterology 1992; 102:10171023.
  • 11
    Lin HC, Tsai YT, Huang CC, Meng HC, Lee FY, Wang SS, Lee SD, et al. Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis. J Hepatol 1994; 21:424429.
  • 12
    McCormick PA, Dick R, Graffeo M, Wagstaff D, Madden A, McIntyre N, Burroughs AK. The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. J Hepatol 1990; 11:221225.
  • 13
    McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, Wagstaff D, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16:11801186.
  • 14
    Navasa M, Garcia-Pagán JC, Chesta J, Bru C, Pizcueta P, Casamitjana R, et al. Cambios postprandiales de la presión portal en la cirrosis hepática. Relación con los niveles de glucagón plasmatico. Gastroenterol Hepatol 1989; 12:231A.
  • 15
    Vorobioff JD, Gamen M, Kravetz D, Picabea E, Villavicencio R, Bordato J, Ruf A, et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. Gastroenterology 2002; 122:916922.
  • 16
    Alvarez D, Miguez C, Podesta A, Terg R, Sanchez MA, Bandi JC, Sanchez S, et al. Postprandial vascular response in patients with cirrhosis. Short-term effects of propranolol administration. Dig Dis Sci 1994; 39:12881293.
  • 17
    Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28:926931.
  • 18
    Sarela AI, Mihaimeed FM, Batten JJ, Davidson BR, Mathie RT. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 1999; 44:749753.
  • 19
    Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114:344351.
  • 20
    Garcia-Pagan JC, Feu F, Navasa M, Bru C, Ruiz dA, Bosch J, Rodes J. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990; 11:189195.
  • 21
    Escorsell A, Feu F, Bordas JM, Garcia-Pagan JC, Luca A, Bosch J, Rodes J. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1996; 24:423429.
  • 22
    Grose RD, Plevris JN, Redhead DN, Bouchier IA, Hayes PC. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis. J Hepatol 1994; 20:542547.
  • 23
    Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989; 96:11101118.
  • 24
    Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999; 19:427438.
  • 25
    Bathal PS, Grossmann HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1:325329.
  • 26
    Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19:411426.
  • 27
    Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19:397410.
  • 28
    Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the Rat. Gastroenterology 1999; 117:12221228.
  • 29
    Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280:G1209G1216.
  • 30
    Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001; 98:88978902.
  • 31
    Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105:741748.
  • 32
    Shah V, Chen AF, Cao S, Hendrickson H, Weiler D, Smith L, Yao J, et al. Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro. Am J Physiol Gastrointest Liver Physiol 2000; 279:G1023G1030.
  • 33
    Blei AT, Gottstein J. Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic response. Hepatology 1986; 6:107111.
  • 34
    Morillas RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, Garcia Pagan JC, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994; 20:15021508.
  • 35
    Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31:12391245.
  • 36
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:16241629.
  • 37
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647655.
  • 38
    Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114:869873.
  • 39
    Jones AL, Bangash IH, Walker J, Simpson KJ, Finlayson ND, Hayes PC. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis. Gut 1995; 36:104109.